Livagen

Livagen is the synthetic four-amino-acid peptide KEDA, discussed for liver support and aging. Reports include improved liver markers inside a stack, extra energy, no noticeable change and unwanted effects. Human half-life and a dependable dose or cycle remain unknown.

Four amino acids, called KEDA. Livagen is synthetic Lys-Glu-Asp-Ala, a short Khavinson bioregulator peptide. Bioregulators are proposed to influence cell activity or gene expression. Its liver association comes from development and marketing; selective delivery to a person's liver is unproven. Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages (Animal context · Accessed 2026-09-30)

Product identity matters. Pure KEDA vials, oral products and liver peptide complexes differ. Svetinorm is not simply oral Livagen; Ovagen has another sequence. Community charts mention subcutaneous, oral, occasional intramuscular and improvised sublingual use; comparable absorption is unknown.

Source context — Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages: Rat cells in culture; no human administration, organ targeting or PK.

Better liver markers and less inflammation. vegasroller described normal liver enzymes and feeling less inflamed after adding injectable Ovagen and Livagen. Their account also includes Vilon, TUDCA and stem-cell treatment; it cannot isolate Livagen's contribution. Best Peptides for the LIVER (Personal report · Accessed 2026-09-30)

Early sensations vary. Delk377 felt wired initially and fine by the course's end; Amzel_Sun reported an energy boost without bloodwork. Neither specifies a first-dose delay or confirms the proposed amount. Livagen dosage and cycle (Community discussion · Accessed 2026-09-30)

Feeling better is not a liver measurement. The energy report has no bloodwork. It conflicts with another commenter's insistence that perceived effects must be placebo; neither position establishes what everyone should feel. Livagen dosage and cycle (Community discussion · Accessed 2026-09-30)

No noticeable change can coexist with uncertainty. Bioenergetic Forum user evan.hinkle noticed no improvement in glycogen-related stamina, but was unsure which liver bioregulator they used. That identity uncertainty limits what the account says about KEDA. Bioregulators (Personal report · Accessed 2026-09-30)

Source context — Best Peptides for the LIVER: Same reporter across replies; multi-agent use; no lab documents. Ovagen dose typo is not Livagen dosing.

Source context — Livagen dosage and cycle: Route unspecified; planned amounts are not confirmed use. No lab documentation.

Source context — Bioregulators: Reporter unsure which liver product; route and amount absent; no date shown.

1 mg proposals versus a 2 mg daily claim. A Biohackers OP considered 1 mg for 20 days; another commenter called 2 mg daily for 30 days a standard. Neither supplies dose-finding evidence, and route is unstated. Livagen dosage and cycle (Community discussion · Accessed 2026-09-30)

Separate injectable chart families. Older vendor/community charts distinguish 2–5 mg subcutaneous once daily for 10–20 days, 2 mg daily for 30 days, and 5–10 mg injectable once daily for about 10 days. A 10 mg/day variant runs 10–14 days. Consistent clock timing is convention, not a demonstrated optimum.

Lower amounts have different origins. A Low-Toxin forum repost describes 100–300 mcg/day subcutaneous Livagen in a valproate combination. Separately, affiliate guide Peptidings proposes 100–500 mcg/day subcutaneous or sublingual by analogy, explicitly as hypothetical. Neither establishes a stand-alone liver regimen. Finally Cured From Post Finasteride Syndrome — page 155 (Secondhand community claim · Accessed 2026-09-30) · Livagen: What the Research Actually Shows (Community guide · Accessed 2026-09-30)

Oral labeled material: roughly 10–40 mg/day. Product charts describe 10 mg capsules, one or two once or twice daily for 10–20 days. Peptide-complex labels are not proven equivalent to injected KEDA. Milligrams and micrograms differ by 1,000.

Longer vendor schedules are a separate family. A vendor-style table steps daily amounts through 500, 1,000, 1,500 and 2,000 mcg across 8–12 weeks. This titration lore does not demonstrate that escalation improves results.

Source context — Livagen dosage and cycle: Route unspecified; planned amounts are not confirmed use. No lab documentation.

Source context — Finally Cured From Post Finasteride Syndrome — page 155: Recounts an Instagram clip; clip inaccessible. Not the poster's own trial.

Source context — Livagen: What the Research Actually Shows: Affiliate disclosure; hypothetical amounts, not user logs. Identity chemistry differs from frozen card.

Within days in one combined account. The liver-thread reporter claimed normal enzymes within a few days of starting injectable Ovagen and Livagen. There is no documented Livagen-only onset. Best Peptides for the LIVER (Personal report · Accessed 2026-09-30)

Early sensations vary. Delk377 felt wired initially and fine by the course's end; Amzel_Sun reported an energy boost without bloodwork. Neither specifies a first-dose delay or confirms the proposed amount. Livagen dosage and cycle (Community discussion · Accessed 2026-09-30)

No reliable single-dose window. These reports establish neither hours of benefit per administration nor predictable benefit after stopping. Bloodwork and subjective feelings are different endpoints. Best Peptides for the LIVER (Personal report · Accessed 2026-09-30) · Livagen dosage and cycle (Community discussion · Accessed 2026-09-30)

A residual reset is community theory. Older community summaries describe residual effects for days to weeks, including a 2–8-week post-course window. This gene-expression narrative establishes neither circulating peptide nor lasting benefit.

No dependable human number. Community summaries contain hours-scale assumptions, not measured human oral or injected elimination. Daily charts, energy, anxiety and liver-marker changes cannot establish how long KEDA stays in blood.

Minutes to hours is an inference. Peptidings describes a short plasma presence expected from peptide breakdown, while acknowledging unknown human kinetics. This is a structural expectation, not a measured Livagen half-life. Livagen: What the Research Actually Shows (Community guide · Accessed 2026-09-30)

Source context — Best Peptides for the LIVER: Same reporter across replies; multi-agent use; no lab documents. Ovagen dose typo is not Livagen dosing.

Source context — Livagen dosage and cycle: Route unspecified; planned amounts are not confirmed use. No lab documentation.

Source context — Livagen: What the Research Actually Shows: Affiliate disclosure; hypothetical amounts, not user logs. Identity chemistry differs from frozen card.

Short-course traditions vary. Older charts describe 10-day, 10–20-day and 20–30-day blocks; oral-kit charts use 10–20 days. Rest claims range from 6–12 weeks to months and two or three yearly courses, sometimes spring/fall or after alcohol, medication or bulking phases.

A 30-day claim with a three-month wait. Few_Bowler_253 advocated 2 mg daily for 30 days, waiting three months and three courses yearly. That is one commenter's claim, not a validated calendar. Livagen dosage and cycle (Community discussion · Accessed 2026-09-30)

Eight to twelve weeks is a different chart tradition. Long lower-dose vendor courses sometimes extend toward 16 weeks. Pulsed-use traditions do not validate year-round use or a universal cycle.

Source context — Livagen dosage and cycle: Route unspecified; planned amounts are not confirmed use. No lab documentation.

Liver dual (most common bioregulator pair): Livagen + Ovagen — framed as complementary liver coverage (KEDA chromatin / protein-synthesis narrative + Ovagen liver–GI function framing; different sequences). Ratios are separate daily doses of each, not a fixed pre-mix. [community]

Vascular + liver trio: Livagen + Ovagen + Vesugen (endothelial/vascular bioregulator) for ‘hepatic + vascular map’ longevity stacks. [community]

Stack ratio honesty: Unlike Wolverine/GLOW pre-mixes, bioregulator stacks are almost always separate products with independent dose charts; no universal Livagen:Ovagen mg ratio is validated. [community]

Digestive multi-organ kit talk: Livagen alongside Svetinorm (crude liver peptide complex — not identical to KEDA), Stamakort (stomach), Suprefort/Pancragen (pancreas), Ventfort (vascular) in broader GI–metabolic bioregulator kits. [community]

Pineal / longevity core: Livagen + Epitalon (AEDG) — different tissues (liver/chromatin vs pineal/telomere stories); often same short-course calendar. [community]

Immune pairing: Livagen + Thymalin or Vilon; some longevity pages also mention Thymosin Alpha-1 / LL-37 as non-bioregulator immune adjuncts — confounded multi-agent logs. [community]

OTC liver adjacency: NAC, milk thistle (silymarin), TUDCA, alpha-lipoic acid commonly co-listed — credit for labs/feel often shared across the stack. [community]

Lifestyle co-credit: Alcohol reduction, sleep, training deload, and diet changes frequently get equal or greater credit when outcomes feel good. [community]

Months of symptoms is an adverse follow-up. Aarons_world95 attributed anxiety and heart problems to 12 days of use and said problems remained eight months later. That account cannot establish causation or bodily half-life. Experiences with livagen? (Personal report · Accessed 2026-09-30)

Serious symptoms should not be explained away. The anxiety and heart-symptom report matters even without a verified diagnosis. It does not establish frequency, but it contradicts blanket claims that bioregulators are invariably mild or that unpleasant sensations prove a helpful reset. Experiences with livagen? (Personal report · Accessed 2026-09-30)

Identity, contamination and interactions are unresolved. Older community notes mention injection-site redness, sting, itch or bruising, plus headache, fatigue or gut upset in mixed stacks. Labels do not establish delivered KEDA or sterility; alcohol and medication interactions are poorly mapped.

Liver disease and vulnerable groups need more than anecdotes. Claims about hepatitis, cirrhosis, fatty liver or alcohol-related damage are not established treatments. Pregnancy, nursing, children, malignancy, serious liver impairment and complex medication use remain evidence gaps. Research-only labeling and athletic eligibility require separate checking; neither is a safety assurance.

Source context — Experiences with livagen?: Amount, route and clinical details absent; positive reply includes a supplier plug.